As shown in Fig. 6, SNHG16 was aberrantly expressed in sarcoma, breast invasion carcinoma, bladder urothelial carcinoma, esophageal carcinoma, stomach adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, rectum adenocarcinoma, lung adenocarcinoma, and lung squamous cell carcinoma when compared with normal control. This evidence concerns the gene SNHG16 and invasive breast carcinoma.